TICKERNERD
Menu
JAZZJAZZHealthcare · Biotechnology

JAZZ Stock Forecast: Jazz Pharmaceuticals Plc Price Predictions for 2026-2027

Last close, 14 Aug 2026
$245
−0.36% on the day

The 20 Wall Street analysts covering Jazz Pharmaceuticals Plc hold a median 12-month price target of $285 — +16.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$15.9B
Ticker Nerd rank
100 / 100
Median analyst target
$285
Analysts covering
20
Total return, dividends reinvested
1W
−4.5%
1M
+2.9%
YTD
+44.1%
1Y
+110.0%
From 52W high
−6.4%
From 52W low
+110.0%
$117
$262
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JAZZ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Jazz Pharmaceuticals Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
100 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
99
Growth
94
Momentum
93
Quality
85
Issuance
82
Revisions
82
Accruals
79
Size
12

Volatility (99): The share price has been relatively steady.

Accruals (79): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

JAZZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JAZZ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250$300Oct 25Jan 26Apr 26Jul 26JAZZHigh $315Median $285Low $196

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says20 analysts
18 Buy1 Hold1 Sell
Low $196Median $285High $315

The green dot is the last close — the median target sits +16.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Aug 2026Morgan StanleyMaintainsOverweight$280 → $283
4 Aug 2026BairdMaintainsOutperform$252 → $280
4 Aug 2026BarclaysMaintainsOverweight$260 → $270
4 Aug 2026JP MorganMaintainsOverweight$265 → $276
4 Aug 2026Morgan StanleyMaintainsOverweight$245 → $280
4 Aug 2026NeedhamMaintainsBuy$282 → $292
4 Aug 2026Piper SandlerMaintainsOverweight$301 → $310
4 Aug 2026TD CowenMaintainsBuy$275 → $300
4 Aug 2026Truist SecuritiesMaintainsBuy$254 → $264
4 Aug 2026Wells FargoMaintainsOverweight$285 → $300
20 July 2026NeedhamMaintainsBuy$255 → $282
20 July 2026NeedhamMaintainsBuy—
17 July 2026Canaccord GenuityInitiatesBuy$290
17 July 2026Canaccord GenuityInitiatesBuy—
14 July 2026BarclaysMaintainsOverweight—
14 July 2026BarclaysMaintainsOverweight$253 → $260
14 July 2026Wells FargoMaintainsOverweight—
14 July 2026Wells FargoMaintainsOverweight$265 → $285
9 July 2026Deutsche BankMaintainsBuy—
9 July 2026Deutsche BankMaintainsBuy$250 → $270

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JAZZ appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

JAZZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.3%
Analysts raising
2
Analysts cutting
4
Fundamentals

Jazz Pharmaceuticals Plc (JAZZ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.8×

Cheaper than 44% of US stocks

Price / sales
3.5×

Cheaper than 37% of US stocks

Price / book
3.3×

Cheaper than 32% of US stocks

EV / EBITDA
9.4×

Cheaper than 41% of US stocks

Growth & margins
Revenue growth (YoY)
15.5%

Higher than 63% of US stocks

Earnings growth (YoY)
15.5%

Higher than 54% of US stocks

Gross margin
90.4%

Higher than 97% of US stocks

Operating margin
26.9%

Higher than 85% of US stocks

Net margin
20.4%

Higher than 83% of US stocks

Returns & dividend
Return on equity
22.1%

Higher than 83% of US stocks

Return on assets
6.9%

Higher than 84% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

JAZZ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JAZZJazz Pharmaceuticals Plc$15.9B
100
BBIOBridgeBio Pharma, Inc.$15.5B
68
EXELExelixis, Inc.$13.3B
98
BMRNBioMarin Pharmaceutical, Inc.$13.0B
59
CORTCorcept Therapeutics, Inc.$12.3B
78
ARWRArrowhead Pharmaceuticals, Inc.$12.1B
57
MDGLMadrigal Pharmaceuticals, Inc.$11.6B
69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Jazz Pharmaceuticals Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JAZZ news & analysis

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Seeking Alpha · 12 Aug 2026positive

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront, adding ABS-1230, a registrational-stage precision therapy for rare KCNT1+ epilepsy, to its pipeline. The company also reported record Q2 2026 revenues of approximately $1.2 billion, driven by strong year-on-year growth in Xywav and Zepzelca.

Why it matters — The acquisition strengthens Jazz's epilepsy division with a late-stage precision therapy, while record revenues highlight continued commercial momentum in its existing portfolio.

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects

Zacks Investment Research · 10 Aug 2026neutral

Zacks Research examines Jazz Pharmaceuticals' international revenue trends and how these figures influence Wall Street's forecasts for the company. The piece highlights the significance of these international numbers in shaping what lies ahead for Jazz.

Why it matters — Investors in JAZZ would want to understand how international revenue performance affects analysts' expectations and the company's outlook.

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Reuters · 10 Aug 2026positive

Jazz Pharmaceuticals announced it would acquire private biotech Actio Biosciences in a deal potentially worth up to $1.32 billion, gaining an experimental therapy for a rare inherited form of epilepsy with no currently approved treatments.

Why it matters — The deal adds a promising pipeline asset targeting an unmet medical need in epilepsy, a therapeutic area core to Jazz's business.

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

PRNewsWire · 10 Aug 2026positive

Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration. The deal adds ABS-1230, Actio's clinical-stage, potential first-in-class small molecule precision therapy for KCNT1+ epilepsy, to Jazz's portfolio.

Why it matters — The acquisition expands Jazz's rare and severe epilepsy pipeline with a potential first-in-class precision therapy, leveraging its development and commercial expertise in the space.

FAQ

Frequently asked questions about JAZZ stock

What is the JAZZ stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Jazz Pharmaceuticals Plc have a median 12-month price target of $285, with estimates ranging from $196 to $315. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JAZZ stock a buy right now?

Of the 20 analysts covering Jazz Pharmaceuticals Plc, 18 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Jazz Pharmaceuticals Plc 100 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JAZZ?

As at 15 Aug 2026, Jazz Pharmaceuticals Plc ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will JAZZ stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +16.3% from the last close, and Ticker Nerd's factor model ranks Jazz Pharmaceuticals Plc 100 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JAZZ stock forecast for 2030?

No analyst covering Jazz Pharmaceuticals Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JAZZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $196 to $315 over the next 12 months.

How has JAZZ stock performed over the past year?

Jazz Pharmaceuticals Plc returned +110.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Jazz Pharmaceuticals Plc do?

Jazz Pharmaceuticals plc is a biopharmaceutical company dedicated to identifying, developing, and commercializing innovative medicines that address unmet medical needs in serious diseases. It maintains a diverse portfolio of marketed products targeting rare epilepsies such as with Epidiolex, sleep disorders including narcolepsy treatments like Xyrem and Xywav, and various cancers through therapies like Zepzelca, Vyxeos, and Ziihera for specific indications including metastatic small cell lung cancer and HER2-positive biliary tract cancer.

What is the latest news on JAZZ?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout". Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront, adding ABS-1230, a registrational-stage precision therapy for rare KCNT1+ epilepsy, to its pipeline. The company also reported record Q2 2026 revenues of approximately $1.2 billion, driven by strong year-on-year growth in Xywav and Zepzelca.

Company

About Jazz Pharmaceuticals Plc.

Jazz Pharmaceuticals plc is a biopharmaceutical company dedicated to identifying, developing, and commercializing innovative medicines that address unmet medical needs in serious diseases. It maintains a diverse portfolio of marketed products targeting rare epilepsies such as with Epidiolex, sleep disorders including narcolepsy treatments like Xyrem and Xywav, and various cancers through therapies like Zepzelca, Vyxeos, and Ziihera for specific indications including metastatic small cell lung cancer and HER2-positive biliary tract cancer. The company also offers treatments for rare diseases, hematology, and neuroscience conditions, supported by a robust pipeline of therapeutics. Jazz Pharmaceuticals plc operates globally with a patient-focused, science-driven approach, advancing research in oncology, neurology, and rare disease areas to transform patient lives. Founded in 2003 and headquartered in Dublin, Ireland, it plays a significant role in the biopharmaceutical market by providing specialized therapies where treatment options are limited.

CEO Ms. Renee D. Gala · 2,890 employees · Ireland · https://www.jazzpharma.com